Adrenaline Tartrate

證據等級: L5

預測適應症: 0 個

Adrenaline Tartrate: Drug Repurposing Evaluation (Prediction Data Pending)

One-Sentence Summary

Adrenaline Tartrate (epinephrine tartrate) is a direct-acting sympathomimetic catecholamine, primarily used in emergency settings for anaphylaxis, cardiac arrest, and severe bronchospasm. No new repurposing indications have been generated by the TxGNN model at this time, as two critical data gaps — missing DrugBank ID mapping and mechanism of action data — prevented the prediction pipeline from running. A full repurposing assessment cannot be completed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Emergency use: anaphylaxis, cardiac arrest, severe bronchospasm
Predicted New Indication	Not available
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
Malaysia Market Status	✓ Marketed
Number of Registrations	5
Recommended Decision	Hold

Why Is a Prediction Not Yet Available?

Adrenaline Tartrate is the tartrate salt form of epinephrine, a well-established catecholamine hormone and neurotransmitter. Pharmacologically, it acts as a potent agonist at both α-adrenergic receptors (vasoconstriction, mydriasis) and β-adrenergic receptors (bronchodilation, positive chronotropy and inotropy), making it irreplaceable in acute life-threatening emergencies.

However, this Evidence Pack was produced without a resolved DrugBank ID, which is the key identifier required to anchor the drug within the TxGNN knowledge graph. Without this linkage, the knowledge-graph (KG) and deep-learning (DL) prediction steps cannot be executed, and no candidate new indications are returned.

Mechanistically, adrenaline’s broad adrenergic profile does offer theoretical repurposing interest — for example, in areas such as glaucoma (topical β-blockade), septic shock vasopressor support, or wound healing modulation — but no model-based prediction is available in this pack to evaluate against.

Malaysia Market Information

Five product registrations are recorded as currently marketed in Malaysia. Unfortunately, the NPRA data retrieval in this cycle did not populate individual license details (authorization numbers, product names, dosage forms, approved indication texts). A direct re-query of the NPRA Product Registration database using the search term “ADRENALINE TARTRATE” is required to retrieve complete records for all five registrations.

Safety Considerations

Package insert safety information — including key warnings and contraindications — was not retrieved in this data cycle. This represents a Blocking data gap that must be resolved before any clinical or regulatory review can proceed.

Please refer to the NPRA-approved package insert for current safety information, including warnings on cardiovascular risk, hyperthyroidism, diabetes, and interactions with MAO inhibitors and tricyclic antidepressants.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline could not be executed due to an unresolved DrugBank ID mapping, and two critical data gaps (safety warnings and MOA) remain open; no repurposing candidate can be evaluated in the absence of a model prediction.

To proceed, the following is needed:

Resolve DrugBank ID — Map “ADRENALINE TARTRATE” to its DrugBank entry (likely DB00668, Epinephrine) to enable full KG + DL prediction
Re-run TxGNN pipeline — Once DrugBank ID is confirmed, regenerate repurposing candidates
Retrieve package insert (DG001 — Blocking) — Download and parse the NPRA/TFDA package insert PDF to populate key warnings and contraindications
Query DrugBank API for MOA (DG002 — High) — Retrieve mechanism of action, pharmacodynamics, and target data for mechanistic relevance analysis
Re-query NPRA license database — Retrieve full registration details (authorization numbers, product names, dosage forms, approved indications) for all 5 registered products
Re-issue Evidence Pack — Once all data gaps are resolved, regenerate a v5 Evidence Pack to support a complete repurposing evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.